- Home
- EDTK vs INAB Comparison
EDTK vs INAB Comparison
Compare EDTK & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDTK | INAB |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 14.2M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EDTK | INAB |
|---|---|---|
| Price | $1.03 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 3.9K | ★ 74.7K |
| Earning Date | 01-16-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.12 |
| 52 Week High | $1.18 | $4.20 |
Technical Indicators
Market Signals| Indicator | EDTK | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 59.19 | 40.61 |
| Support Level | $0.96 | $1.17 |
| Resistance Level | $1.06 | $2.59 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 85.44 | 12.86 |
Price Performance
Historical ComparisonAbout EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.